Clinical Prior Authorization Update for VMAT2 Inhibitors Scheduled for August 13, 2020

Clinical Prior Authorization Update for VMAT2 Inhibitors Scheduled for August 13, 2020

VDP routinely updates existing clinical prior authorization criteria to reflect recent FDA-approved indications or safety information from the product package insert. FirstCare will revise the Austedo (deutetrabenazine) criteria within the Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors clinical prior authorization on August 13, 2020: 

• Austedo is indicated for the treatment of tardive dyskinesia and Huntington-induced chorea. Current criteria require prescribing by, or its use overseen by, a neurologist or psychiatrist 
• Revised criteria will remove the specialist requirement for only the treatment of tardive dyskinesia ◦ There will not be a change for the treatment of Huntington-induced chorea due to an increased risk of suicidality or suicidal ideation associated with Huntington disease